Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation
KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRASG12D inhibitors (hits 1-4) by using structure-based virtual screening and biological evaluation. The in vitro assays indicated that t...
Saved in:
Main Authors: | , , , , , |
---|---|
格式: | 图书 |
出版: |
Frontiers Media S.A.,
2022-12-01T00:00:00Z.
|
主题: | |
在线阅读: | Connect to this object online. |
标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
因特网
Connect to this object online.3rd Floor Main Library
索引号: |
A1234.567 |
---|---|
复印件 1 | 可用 |